Alembic Pharma Share Price
Alembic Pharma Share Price Today
As of 18 Jul 2026, Alembic Pharma share price is ₹825.10. The stock opened at ₹842.85, compared to its previous close of ₹839.75. During today's trading session, Alembic Pharma share price moved in the range of ₹821.00 to ₹842.85, with an average price of ₹831.92 for the day. Looking at its last 52-week, the stock has touched a low of ₹635.80 and a high of ₹1,038.00. On the performance front, Alembic Pharma share price has increased by 6.48% over the last six months and is down 20.36% on a year-on-year basis.
Alembic Pharma Returns Calculator
Alembic Pharma Shareholder Returns
Alembic Pharma Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,63,815.00 | 36.73 | 5.05 | 14.85% | 0.55 | 18.72% | 18.85 | 0.91% | 0.56 | 10.90 |
| Divis Laboratories | 1,92,678.00 | 61.36 | 9.40 | 16.19% | 0.00 | 21.00% | 9.43 | 0.50% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,61,323.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,14,585.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Zydus Lifesciences | 1,13,990.00 | 17.39 | 3.23 | 19.69% | 0.35 | 20.30% | 3.70 | 0.11% | 0.39 | 35.38 |
| Lupin | 1,11,661.00 | 19.83 | 4.71 | 27.01% | 0.03 | 27.44% | 3.51 | 0.78% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,896.00 | 1.05 | 0.12 | 12.65% | 0.42 | 12.97% | 5.05 | 0.05% | 0.54 | 49.37 |
| Dr. Reddy's Laboratories | 1,01,067.00 | 24.97 | 2.75 | 11.64% | 0.15 | 13.65% | 3.32 | 0.64% | 0.63 | 38.68 |
| Aurobindo Pharma | 89,097.90 | 25.44 | 2.35 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,639.30 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
Alembic Pharma Financials
Income Statement · Consolidated
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | ₹7,344.90 | ₹6,672.08 | ₹6,228.63 | ₹5,652.62 |
| Other Income | ₹54.41 | ₹42.55 | ₹28.30 | ₹2.74 |
| Total Revenue | ₹7,399.31 | ₹6,714.63 | ₹6,256.93 | ₹5,655.36 |
| Total Expenses | ₹6,638.62 | ₹6,021.20 | ₹5,624.13 | ₹5,269.86 |
| Profit Before Tax | ₹693.95 | ₹707.18 | ₹631.83 | ₹354.59 |
| Tax | ₹23.12 | ₹125.17 | ₹16.01 | ₹12.60 |
| Profit After Tax | ₹670.83 | ₹582.01 | ₹615.82 | ₹341.99 |
| EPS - Basic | ₹34.33 | ₹29.68 | ₹31.33 | ₹17.40 |
| EPS - Diluted | ₹34.33 | ₹29.68 | ₹31.33 | ₹17.40 |
Cash Flow · Consolidated
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Profit before tax | ₹693.95 | ₹707.18 | ₹631.83 | ₹354.59 |
| Income before WC changes | ₹1,143.26 | ₹1,080.71 | ₹918.69 | ₹842.20 |
| Change in Assets | -₹265.52 | -₹1,088.66 | -₹146.81 | ₹38.70 |
| Change in Liabilities | ₹8.70 | ₹167.30 | ₹51.17 | -₹96.26 |
| Change in WC | -₹256.82 | -₹921.36 | -₹95.64 | -₹57.56 |
| Cash flow from Operations | ₹782.73 | ₹87.96 | ₹803.20 | ₹723.95 |
| Cash flow from Investing | -₹506.06 | -₹568.41 | -₹320.61 | -₹447.60 |
| Cash flow from Financing | -₹163.78 | ₹443.72 | -₹437.86 | -₹261.96 |
| Total Cash Flow | ₹112.89 | -₹36.73 | ₹44.73 | ₹14.39 |
| Cash (Start of the year) | ₹83.48 | ₹120.21 | ₹75.48 | ₹61.09 |
| Cash (End of the year) | ₹196.37 | ₹83.48 | ₹120.21 | ₹75.48 |
Balance Sheet · Consolidated
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Non-Current Assets | ₹4,219.99 | ₹3,685.15 | ₹3,367.02 | ₹3,272.81 |
| Current Assets | ₹4,542.59 | ₹4,087.80 | ₹3,078.56 | ₹2,910.02 |
| Total Assets | ₹8,762.58 | ₹7,772.95 | ₹6,445.58 | ₹6,182.83 |
| Current Liabilities | ₹2,593.83 | ₹2,412.35 | ₹1,454.99 | ₹1,636.93 |
| Net Current Asset | ₹1,948.76 | ₹1,675.45 | ₹1,623.57 | ₹1,273.09 |
| Non-Current Liabilities | ₹499.77 | ₹171.08 | ₹172.39 | ₹175.43 |
| Equity Capital | ₹5,668.98 | ₹5,189.52 | ₹4,818.20 | ₹4,370.47 |
| Total Equity & Liabilities | ₹8,762.58 | ₹7,772.95 | ₹6,445.58 | ₹6,182.83 |
Income Statement · Standalone
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | ₹6,651.38 | ₹6,032.63 | ₹5,874.06 | ₹5,149.00 |
| Other Income | ₹55.90 | ₹47.88 | ₹31.32 | ₹3.55 |
| Total Revenue | ₹6,707.28 | ₹6,080.51 | ₹5,905.38 | ₹5,152.55 |
| Total Expenses | ₹5,986.18 | ₹5,484.79 | ₹5,201.15 | ₹4,806.62 |
| Profit Before Tax | ₹654.11 | ₹608.59 | ₹704.23 | ₹345.93 |
| Tax | ₹13.69 | ₹105.47 | ₹37.75 | -₹0.80 |
| Profit After Tax | ₹640.42 | ₹503.12 | ₹666.48 | ₹346.73 |
| EPS - Basic | ₹32.58 | ₹25.60 | ₹33.91 | ₹17.64 |
| EPS - Diluted | ₹32.58 | ₹25.60 | ₹33.91 | ₹17.64 |
Cash Flow · Standalone
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Profit before tax | ₹654.11 | ₹608.59 | ₹704.23 | ₹345.93 |
| Income before WC changes | ₹1,082.56 | ₹973.66 | ₹988.44 | ₹794.42 |
| Change in Assets | -₹184.71 | -₹828.50 | -₹224.36 | ₹33.82 |
| Change in Liabilities | -₹8.84 | ₹127.07 | ₹18.72 | -₹44.21 |
| Change in WC | -₹193.55 | -₹701.43 | -₹205.64 | -₹10.39 |
| Cash flow from Operations | ₹809.47 | ₹226.56 | ₹772.77 | ₹730.25 |
| Cash flow from Investing | -₹483.43 | -₹636.07 | -₹329.02 | -₹460.98 |
| Cash flow from Financing | -₹317.60 | ₹403.61 | -₹445.29 | -₹261.16 |
| Total Cash Flow | ₹8.44 | -₹5.90 | -₹1.54 | ₹8.11 |
| Cash (Start of the year) | ₹14.23 | ₹20.13 | ₹21.67 | ₹13.56 |
| Cash (End of the year) | ₹22.67 | ₹14.23 | ₹20.13 | ₹21.67 |
Balance Sheet · Standalone
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Non-Current Assets | ₹4,150.24 | ₹3,790.07 | ₹3,409.99 | ₹3,350.19 |
| Current Assets | ₹4,001.00 | ₹3,766.19 | ₹2,988.56 | ₹2,780.23 |
| Total Assets | ₹8,151.24 | ₹7,556.26 | ₹6,398.55 | ₹6,130.42 |
| Current Liabilities | ₹2,356.15 | ₹2,199.59 | ₹1,327.22 | ₹1,551.30 |
| Net Current Asset | ₹1,644.85 | ₹1,566.60 | ₹1,661.34 | ₹1,228.93 |
| Non-Current Liabilities | ₹179.83 | ₹161.93 | ₹162.42 | ₹164.83 |
| Equity Capital | ₹5,615.26 | ₹5,194.74 | ₹4,908.91 | ₹4,414.29 |
| Total Equity & Liabilities | ₹8,151.24 | ₹7,556.26 | ₹6,398.55 | ₹6,130.42 |
About Alembic Pharma
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing and marketing Indian Formulations, International Generics, and Active Pharmaceutical Ingredients (APIs) across the globe. It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopedic and Gynecology. Its products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It also has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its Indian Formulations.
Alembic Pharma Financial Highlights
- Revenue: Alembic Pharma reported revenue of ₹7,399.31 crore in FY26 vs ₹6,714.63 crore in FY25. It showed an increase of 10.20% on a yearly basis.
- Operating Profit: Alembic Pharma reported an operating profit of ₹693.95 crore in FY26 vs ₹707.18 crore in FY25. It showed a decrease of 1.87% on a year-on-year basis.
- Net Profit: Alembic Pharma reported a net profit of ₹670.83 crore in FY26 vs ₹582.01 crore in FY25. It showed an increase of 15.26% on a yearly basis.
Alembic Pharma Quarterly Result Highlights
- Alembic Pharma reported revenue of ₹1,873.22 crore in Mar 2026, compared with ₹1,891.81 crore in Dec 2025, representing a decrease of 0.98% on a quarter-on-quarter (QoQ) basis.
- Alembic Pharma reported an operating profit of ₹118.62 crore in Mar 2026, compared with ₹161.50 crore in Dec 2025, representing a decrease of 26.55% on a quarter-on-quarter (QoQ) basis.
- Alembic Pharma reported a profit of ₹201.53 crore in Mar 2026, compared with ₹131.95 crore in Dec 2025, reflecting an increase of 52.73% on a QoQ basis.
- The earnings per share (EPS) of Alembic Pharma stood at ₹34.33 during Mar 2026.
Similar Stocks
FAQs on Alembic Pharma Share Price
What is Alembic Pharma share price today?
Alembic Pharma share price is ₹825.10 as on 17 Jul, 2026, 15:59 IST.
How has the Alembic Pharma share price performed in the past?
In the last 1 year, Alembic Pharma delivered a return of -20.36%. The Alembic Pharma share price hit a high of ₹1,038.00 and low of ₹635.80.
How much is the Mutual Fund shareholding in Alembic Pharma shares?
The Mutual Fund Shareholding in Alembic Pharma was 8.73% at the end of Jun 2026.
What is the the 52-week high and low of Alembic Pharma shares ?
The 52-week high and low of Alembic Pharma share is ₹1,038.00 and ₹635.80 as of 17 Jul, 2026.
What is the market cap of Alembic Pharma?
The market capitalisation of Alembic Pharma is ₹16,223.30 Crores as on 17 Jul, 2026.
What are the stock symbols of Alembic Pharma?
The stock symbol of Alembic Pharma is APLLTD on the NSE, 533573 on the BSE, and the ISIN is INE901L01018.
What was yesterday's closing price of Alembic Pharma shares ?
Alembic Pharma shares closed yesterday at ₹839.75 on NSE & ₹841.35 on BSE
How to buy Alembic Pharma shares?
To buy Alembic Pharma shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Alembic Pharma shares on Holidays?
No, shares of Alembic Pharma or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Alembic Pharma shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Alembic Pharma?
The PE and PB ratio of Alembic Pharma is 19.28 and 2.29 respectively, as on 17 Jul, 2026, 15:59 IST.